Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD K BOGAN

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1538347661
CMS profile
160258
Location
COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$142,080.35

169 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD K BOGAN

NPI 1538347661 · CMS profile ID 160258

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

169 matching records · $142,080.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 169 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–169 of 169.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $7.5602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183077 CMS
JAZZ PHARMACEUTICALS INC. $47.0002/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183085 CMS
JAZZ PHARMACEUTICALS INC. $27.3302/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183097 CMS
JAZZ PHARMACEUTICALS INC. $646.1702/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183073 CMS
JAZZ PHARMACEUTICALS INC. $154.9102/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183087 CMS
JAZZ PHARMACEUTICALS INC. $11.7602/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684179409 CMS
JAZZ PHARMACEUTICALS INC. $413.6902/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183045 CMS
JAZZ PHARMACEUTICALS INC. $3,500.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183075 CMS
Novartis Pharmaceuticals Corporation $17.1802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659116667 CMS
JAZZ PHARMACEUTICALS INC. $105.3602/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183061 CMS
JAZZ PHARMACEUTICALS INC. $24.6602/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183093 CMS
JAZZ PHARMACEUTICALS INC. $3,500.0002/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183047 CMS
JAZZ PHARMACEUTICALS INC. $124.3502/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183083 CMS
JAZZ PHARMACEUTICALS INC. $33.0001/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684155297 CMS
JAZZ PHARMACEUTICALS INC. $8,840.0001/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684155299 CMS
JAZZ PHARMACEUTICALS INC. $570.0001/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183043 CMS
JAZZ PHARMACEUTICALS INC. $18.4501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684179407 CMS
JAZZ PHARMACEUTICALS INC. $125.0001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183491 CMS
JAZZ PHARMACEUTICALS INC. $125.0001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684183785 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $142,080.35 169
PY2020 $102,269.22 118
PY2021 $131,969.15 135
PY2022 $157,937.91 156
PY2023 $208,345.57 229
PY2024 $96,427.18 158
PY2025 $231,680.91 191

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $188,889.23 21
PY2025 Principal investigator $893,595.41 524
PY2024 Recipient $141,658.73 17
PY2024 Principal investigator $546,297.96 292
PY2023 Recipient $1,858.24 5
PY2023 Principal investigator $780,969.56 153
PY2022 Principal investigator $310,170.01 61
PY2021 Recipient $2,452.50 1
PY2021 Principal investigator $524,293.17 76
PY2020 Recipient $3,733.38 36
PY2020 Principal investigator $424,260.96 105
PY2019 Recipient $836.61 2
PY2019 Principal investigator $220,311.79 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

545 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $156,452.60 12/31/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554185
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208612891
Principal investigator 1 Alkermes, Inc. $706.00 12/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614136
Principal investigator 1 Alkermes, Inc. $6,100.00 12/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624931
Principal investigator 1 Alkermes, Inc. $2,152.00 12/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625165
Principal investigator 1 Alkermes, Inc. $1,317.00 12/23/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626448
Principal investigator 1 PFIZER INC. $1,339.39 12/19/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228736313
Principal investigator 1 Alkermes, Inc. $2,083.00 12/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624300
Principal investigator 1 Alkermes, Inc. $2,133.00 12/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624698
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,087.70 12/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262732
Recipient Takeda Pharmaceuticals U.S.A., Inc. $650.00 12/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262734
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 12/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262736
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 12/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262738
Principal investigator 1 Alkermes, Inc. $136.80 12/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616891
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.48 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737795
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.01 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737797
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737799
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737801
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737803
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.24 11/24/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737805
Principal investigator 1 Alkermes, Inc. $1,891.00 11/19/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613689
Principal investigator 1 Alkermes, Inc. $2,512.00 11/19/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615395
Principal investigator 1 Alkermes, Inc. $6,588.00 11/19/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619421
Principal investigator 1 Alkermes, Inc. $5,171.00 11/19/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623164
Principal investigator 1 Breas Medical, Inc. $131.79 11/19/2025 Non-covered Recipient Entity
Bogan Sleep Consultants
Vivo NOVA No dispute reported 06/30/2026 1249851740
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,234.70 11/19/2025 Covered Recipient Physician A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223262730
Principal investigator 1 Alkermes, Inc. $2,083.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613245
Principal investigator 1 Alkermes, Inc. $280.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613247
Principal investigator 1 Alkermes, Inc. $2,133.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614140
Principal investigator 1 Alkermes, Inc. $2,133.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617331
Principal investigator 1 Alkermes, Inc. $2,133.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620115
Principal investigator 1 Alkermes, Inc. $1,133.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621210
Principal investigator 1 Alkermes, Inc. $2,133.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622908
Principal investigator 1 Alkermes, Inc. $280.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622910
Principal investigator 1 Alkermes, Inc. $2,083.00 11/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626654
Principal investigator 1 Alkermes, Inc. $259.54 11/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613241
Principal investigator 1 Alkermes, Inc. $54.72 11/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616049
Recipient Takeda Pharmaceuticals U.S.A., Inc. $34,825.05 11/03/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262728
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245553791
Principal investigator 1 LivaNova USA, Inc. $691.25 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245553795
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554004
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554008
Principal investigator 1 LivaNova USA, Inc. $691.25 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554012
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554017
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554021
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554025
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554029
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554033
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554038
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554042
Principal investigator 1 LivaNova USA, Inc. $33.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554046
Principal investigator 1 LivaNova USA, Inc. $1,028.75 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554147
Principal investigator 1 LivaNova USA, Inc. $725.00 10/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554152
Principal investigator 1 Alkermes, Inc. $280.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613031
Principal investigator 1 Alkermes, Inc. $3,352.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613243
Principal investigator 1 Alkermes, Inc. $4,272.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613667
Principal investigator 1 Alkermes, Inc. $2,005.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615213
Principal investigator 1 Alkermes, Inc. $706.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617113
Principal investigator 1 Alkermes, Inc. $5,041.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617329
Principal investigator 1 Alkermes, Inc. $2,135.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618469
Principal investigator 1 Alkermes, Inc. $706.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620568
Principal investigator 1 Alkermes, Inc. $5,171.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622243
Principal investigator 1 Alkermes, Inc. $280.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626030
Principal investigator 1 Alkermes, Inc. $752.00 10/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626900
Principal investigator 1 Alkermes, Inc. $1,500.00 10/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614346
Principal investigator 1 Alkermes, Inc. $1,879.00 10/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615197
Principal investigator 1 Alkermes, Inc. $6,667.00 10/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615383
Principal investigator 1 Alkermes, Inc. $615.00 10/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620325
Principal investigator 1 Alkermes, Inc. $1,300.00 10/10/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620570
Principal investigator 1 Breas Medical, Inc. $65.67 10/09/2025 Non-covered Recipient Entity
Bogan Sleep Consultants
Vivo NOVA No dispute reported 06/30/2026 1238854144
Principal investigator 1 Alkermes, Inc. $280.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616051
Principal investigator 1 Alkermes, Inc. $280.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617739
Principal investigator 1 Alkermes, Inc. $280.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617741
Principal investigator 1 Alkermes, Inc. $280.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618205
Principal investigator 1 Alkermes, Inc. $1,133.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621847
Principal investigator 1 Alkermes, Inc. $280.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624732
Principal investigator 1 Alkermes, Inc. $1,133.00 10/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624935
Principal investigator 1 Alkermes, Inc. $71.60 10/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616515
Principal investigator 1 Alkermes, Inc. $225.25 10/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618203
Principal investigator 1 Alkermes, Inc. $259.54 10/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620996
Principal investigator 1 Alkermes, Inc. $94.00 10/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624730
Principal investigator 1 Alkermes, Inc. $54.72 10/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626450
Principal investigator 1 Alkermes, Inc. $280.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208612955
Principal investigator 1 Alkermes, Inc. $6,588.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614467
Principal investigator 1 Alkermes, Inc. $3,352.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616173
Principal investigator 1 Alkermes, Inc. $2,135.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617443
Principal investigator 1 Alkermes, Inc. $706.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618609
Principal investigator 1 Alkermes, Inc. $2,094.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619295
Principal investigator 1 Alkermes, Inc. $5,041.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620696
Principal investigator 1 Alkermes, Inc. $752.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621124
Principal investigator 1 Alkermes, Inc. $6,588.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621518
Principal investigator 1 Alkermes, Inc. $4,272.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622187
Principal investigator 1 Alkermes, Inc. $5,041.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622189
Principal investigator 1 Alkermes, Inc. $5,171.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623540
Principal investigator 1 Alkermes, Inc. $6,100.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623740
Principal investigator 1 Alkermes, Inc. $2,005.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623742
Principal investigator 1 Alkermes, Inc. $280.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624424
Principal investigator 1 Alkermes, Inc. $2,005.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625079
Principal investigator 1 Alkermes, Inc. $752.00 09/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625303
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,866.50 09/12/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262726
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22,847.50 09/10/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737767
Principal investigator 1 Alkermes, Inc. $739.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614046
Principal investigator 1 Alkermes, Inc. $752.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614048
Principal investigator 1 Alkermes, Inc. $712.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614475
Principal investigator 1 Alkermes, Inc. $2,133.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618121
Principal investigator 1 Alkermes, Inc. $752.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619063
Principal investigator 1 Alkermes, Inc. $752.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619801
Principal investigator 1 Alkermes, Inc. $2,133.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620912
Principal investigator 1 Alkermes, Inc. $1,833.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622415
Principal investigator 1 Alkermes, Inc. $280.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622419
Principal investigator 1 Alkermes, Inc. $2,133.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624190
Principal investigator 1 Alkermes, Inc. $2,083.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625313
Principal investigator 1 Alkermes, Inc. $2,133.00 09/08/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625786
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613175
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613385
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614927
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618833
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619797
Principal investigator 1 Alkermes, Inc. $150.40 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621122
Principal investigator 1 Alkermes, Inc. $185.50 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622185
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626800
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $81.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737759
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $652.47 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737763
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $81.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737765
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737769
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737771
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737775
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737779
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $81.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737781
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737783
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737785
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737787
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 09/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737789
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 09/01/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525159
Principal investigator 1 Alkermes, Inc. $1,196.53 08/27/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618301
Principal investigator 1 Alkermes, Inc. $1,196.53 08/27/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626108
Principal investigator 1 Alkermes, Inc. $6,100.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613387
Principal investigator 1 Alkermes, Inc. $2,135.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614709
Principal investigator 1 Alkermes, Inc. $3,352.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616413
Principal investigator 1 Alkermes, Inc. $6,100.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617031
Principal investigator 1 Alkermes, Inc. $3,352.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620908
Principal investigator 1 Alkermes, Inc. $2,094.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621522
Principal investigator 1 Alkermes, Inc. $2,094.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621524
Principal investigator 1 Alkermes, Inc. $4,272.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623318
Principal investigator 1 Alkermes, Inc. $280.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625968
Principal investigator 1 Alkermes, Inc. $2,135.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626172
Principal investigator 1 Alkermes, Inc. $4,272.00 08/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626584
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623014
Principal investigator 1 Alkermes, Inc. $276.00 08/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617859
Principal investigator 1 Alkermes, Inc. $2,054.00 08/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625083
Principal investigator 1 Alkermes, Inc. $136.80 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613383
Principal investigator 1 Alkermes, Inc. $6,724.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618357
Principal investigator 1 Alkermes, Inc. $6,724.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618615
Principal investigator 1 Alkermes, Inc. $4,273.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619799
Principal investigator 1 Alkermes, Inc. $1,133.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622193
Principal investigator 1 Alkermes, Inc. $38.82 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623316
Principal investigator 1 Alkermes, Inc. $4,273.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623962
Principal investigator 1 Alkermes, Inc. $54.72 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625301
Principal investigator 1 Alkermes, Inc. $280.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625309
Principal investigator 1 Alkermes, Inc. $4,273.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625553
Principal investigator 1 Alkermes, Inc. $6,724.00 08/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626174
Recipient Takeda Pharmaceuticals U.S.A., Inc. $50,533.60 08/06/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262722
Recipient Takeda Pharmaceuticals U.S.A., Inc. $15,574.00 08/06/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262724
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,797.38 07/25/2025 Covered Recipient Physician A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223262720
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 07/23/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737777
Principal investigator 1 LivaNova USA, Inc. $135.00 07/18/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245553788
Principal investigator 1 LivaNova USA, Inc. $135.00 07/18/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554176
Principal investigator 1 Alkermes, Inc. $688.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614264
Principal investigator 1 Alkermes, Inc. $6,136.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614479
Principal investigator 1 Alkermes, Inc. $2,125.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614717
Principal investigator 1 Alkermes, Inc. $1,892.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614719
Principal investigator 1 Alkermes, Inc. $712.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617445
Principal investigator 1 Alkermes, Inc. $712.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621732
Principal investigator 1 Alkermes, Inc. $4,832.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624428
Principal investigator 1 Alkermes, Inc. $276.00 07/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626804
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,970.15 07/16/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262718
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,352.74 07/11/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737793
Principal investigator 1 Alkermes, Inc. $2,028.00 07/09/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620484
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 07/09/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737761
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 07/09/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737773
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $993.00 07/09/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737791
Recipient Takeda Pharmaceuticals U.S.A., Inc. $5,500.00 07/09/2025 Covered Recipient Physician A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223262712
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 07/09/2025 Covered Recipient Physician A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223262714
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 07/09/2025 Covered Recipient Physician A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223262716
Principal investigator 1 Alkermes, Inc. $1.74 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614925
Principal investigator 1 Alkermes, Inc. $93.50 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616797
Principal investigator 1 Alkermes, Inc. $25.70 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618353
Principal investigator 1 Alkermes, Inc. $74.24 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619549
Principal investigator 1 Alkermes, Inc. $8.04 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621965
Principal investigator 1 Alkermes, Inc. $3.50 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622599
Principal investigator 1 Alkermes, Inc. $21.40 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623538
Principal investigator 1 Alkermes, Inc. $109.20 07/02/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623958
Principal investigator 1 Alkermes, Inc. $1,196.53 06/27/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617005
Principal investigator 1 Alkermes, Inc. $1,196.53 06/27/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619257
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,033.00 06/25/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262710
Principal investigator 1 Alkermes, Inc. $3.48 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612905
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612969
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613411
Principal investigator 1 Alkermes, Inc. $51.40 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614064
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614292
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614302
Principal investigator 1 Alkermes, Inc. $11.76 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614499
Principal investigator 1 Alkermes, Inc. $10.50 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614959
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615159
Principal investigator 1 Alkermes, Inc. $100.30 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615173
Principal investigator 1 Alkermes, Inc. $3.48 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615287
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615461
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615989
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616109
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616363
Principal investigator 1 Alkermes, Inc. $3.50 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616443
Principal investigator 1 Alkermes, Inc. $5.60 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616813
Principal investigator 1 Alkermes, Inc. $58.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616851
Principal investigator 1 Alkermes, Inc. $24.12 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617013
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617201
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617281
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618055
Principal investigator 1 Alkermes, Inc. $19.60 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618083
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618153
Principal investigator 1 Alkermes, Inc. $31.36 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618317
Principal investigator 1 Alkermes, Inc. $17.12 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619585
Principal investigator 1 Alkermes, Inc. $145.60 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619821
Principal investigator 1 Alkermes, Inc. $59.92 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619839
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620508
Principal investigator 1 Alkermes, Inc. $93.50 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620856
Principal investigator 1 Alkermes, Inc. $50.00 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620934
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621478
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621766
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621782
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621999
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622211
Principal investigator 1 Alkermes, Inc. $254.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622213
Principal investigator 1 Alkermes, Inc. $205.60 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622837
Principal investigator 1 Alkermes, Inc. $231.30 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622839
Principal investigator 1 Alkermes, Inc. $50.00 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622848
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622850
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623284
Principal investigator 1 Alkermes, Inc. $148.48 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623348
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623366
Principal investigator 1 Alkermes, Inc. $148.48 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623566
Principal investigator 1 Alkermes, Inc. $2.14 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624020
Principal investigator 1 Alkermes, Inc. $42.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624242
Principal investigator 1 Alkermes, Inc. $15.68 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624592
Principal investigator 1 Alkermes, Inc. $27.44 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624840
Principal investigator 1 Alkermes, Inc. $24.12 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625259
Principal investigator 1 Alkermes, Inc. $51.40 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625331
Principal investigator 1 Alkermes, Inc. $4.90 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625561
Principal investigator 1 Alkermes, Inc. $16.08 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625728
Principal investigator 1 Alkermes, Inc. $51.40 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625802
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626000
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626376
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626522
Principal investigator 1 Alkermes, Inc. $359.80 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626840
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626848
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,027.00 06/13/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737749
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 06/13/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737755
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,895.00 06/13/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737757
Principal investigator 1 Alkermes, Inc. $1,880.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616545
Principal investigator 1 Alkermes, Inc. $1,980.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618257
Principal investigator 1 Alkermes, Inc. $2,125.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622723
Principal investigator 1 Alkermes, Inc. $4,691.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622725
Principal investigator 1 Alkermes, Inc. $1,892.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622727
Principal investigator 1 Alkermes, Inc. $688.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622964
Principal investigator 1 Alkermes, Inc. $1,880.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625183
Principal investigator 1 Alkermes, Inc. $276.00 06/11/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626070
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737747
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737751
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.48 06/11/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737753
Principal investigator 1 Alkermes, Inc. $30.61 06/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623638
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613990
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615671
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615913
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616567
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618999
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619733
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619735
Principal investigator 1 Alkermes, Inc. $136.80 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620065
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620419
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621272
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621274
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623260
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623910
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624386
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624568
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625017
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625704
Principal investigator 1 Alkermes, Inc. $280.00 06/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619645
Principal investigator 1 Alkermes, Inc. $2,157.00 06/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621188
Principal investigator 1 Alkermes, Inc. $280.00 06/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622894
Principal investigator 1 Alkermes, Inc. $280.00 06/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623406
Principal investigator 1 Alkermes, Inc. $280.00 06/04/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624046
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,893.50 06/04/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262708
Principal investigator 1 Alkermes, Inc. $712.00 05/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614330
Principal investigator 1 Alkermes, Inc. $712.00 05/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619379
Principal investigator 1 Alkermes, Inc. $712.00 05/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619869
Principal investigator 1 Alkermes, Inc. $712.00 05/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622473
Principal investigator 1 Alkermes, Inc. $712.00 05/16/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623802
Principal investigator 1 LivaNova USA, Inc. $16.88 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245553784
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554000
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554050
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554054
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554058
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554063
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554066
Principal investigator 1 LivaNova USA, Inc. $16.88 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554070
Principal investigator 1 LivaNova USA, Inc. $16.88 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554074
Principal investigator 1 LivaNova USA, Inc. $16.88 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554077
Principal investigator 1 LivaNova USA, Inc. $1,835.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554080
Principal investigator 1 LivaNova USA, Inc. $1,835.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554085
Principal investigator 1 LivaNova USA, Inc. $590.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554088
Principal investigator 1 LivaNova USA, Inc. $590.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554092
Principal investigator 1 LivaNova USA, Inc. $1,835.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554096
Principal investigator 1 LivaNova USA, Inc. $337.50 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554100
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554103
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554107
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554113
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554120
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554124
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554127
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554131
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554134
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554138
Principal investigator 1 LivaNova USA, Inc. $10,662.52 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554143
Principal investigator 1 LivaNova USA, Inc. $10,662.52 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554184
Principal investigator 1 LivaNova USA, Inc. $1,835.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554272
Principal investigator 1 LivaNova USA, Inc. $33.75 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554277
Principal investigator 1 LivaNova USA, Inc. $337.50 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554281
Principal investigator 1 LivaNova USA, Inc. $270.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554284
Principal investigator 1 LivaNova USA, Inc. $590.00 05/16/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554288
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,572.60 05/14/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262706
Principal investigator 1 Alkermes, Inc. $2,073.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614382
Principal investigator 1 Alkermes, Inc. $276.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615883
Principal investigator 1 Alkermes, Inc. $3,988.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618015
Principal investigator 1 Alkermes, Inc. $688.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624102
Principal investigator 1 Alkermes, Inc. $5,989.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624346
Principal investigator 1 Alkermes, Inc. $3,281.00 05/07/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626302
Principal investigator 1 Alkermes, Inc. $1,133.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613237
Principal investigator 1 Alkermes, Inc. $2,083.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613447
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613663
Principal investigator 1 Alkermes, Inc. $2,083.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613876
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614783
Principal investigator 1 Alkermes, Inc. $1,384.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615561
Principal investigator 1 Alkermes, Inc. $2,157.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615815
Principal investigator 1 Alkermes, Inc. $1,384.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616027
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616257
Principal investigator 1 Alkermes, Inc. $2,157.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616259
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617111
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617325
Principal investigator 1 Alkermes, Inc. $1,133.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620321
Principal investigator 1 Alkermes, Inc. $2,630.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620560
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621596
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622898
Principal investigator 1 Alkermes, Inc. $280.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624050
Principal investigator 1 Alkermes, Inc. $2,157.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624290
Principal investigator 1 Alkermes, Inc. $2,083.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626026
Principal investigator 1 Alkermes, Inc. $2,083.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626424
Principal investigator 1 Alkermes, Inc. $2,630.00 05/05/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626650
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 04/28/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525148
Principal investigator 1 Alkermes, Inc. $118.56 04/25/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614649
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $19,385.00 04/25/2025 Non-covered Recipient Entity
BoganSleep Consultants, LLC
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243531854
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616969
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621458
Principal investigator 1 Alkermes, Inc. $1,880.00 04/21/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618739
Principal investigator 1 Alkermes, Inc. $3,988.00 04/21/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621640
Principal investigator 1 Alkermes, Inc. $1,880.00 04/21/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622527
Principal investigator 1 Alkermes, Inc. $2,073.00 04/21/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625672
Principal investigator 1 Alkermes, Inc. $2,125.00 04/21/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626074
Principal investigator 1 Alkermes, Inc. $102.80 04/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623782
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11,484.75 04/02/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262704
Principal investigator 1 Alkermes, Inc. $1,196.53 03/20/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615107
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder No dispute reported 06/30/2026 1243525153
Recipient Takeda Pharmaceuticals U.S.A., Inc. $16,831.50 03/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262702
Principal investigator 1 Alkermes, Inc. $82.08 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615425
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615525
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615881
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616081
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616325
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617159
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617171
Principal investigator 1 Alkermes, Inc. $52.48 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617399
Principal investigator 1 Alkermes, Inc. $77.64 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617773
Principal investigator 1 Alkermes, Inc. $52.48 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617905
Principal investigator 1 Alkermes, Inc. $228.53 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618405
Principal investigator 1 Alkermes, Inc. $77.64 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618753
Principal investigator 1 Alkermes, Inc. $75.80 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620085
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621164
Principal investigator 1 Alkermes, Inc. $82.08 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621887
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625343
Principal investigator 1 Alkermes, Inc. $228.53 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626078
Principal investigator 1 Alkermes, Inc. $136.80 03/03/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626700
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737653
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737715
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737717
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737729
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,986.00 02/21/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737655
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,327.00 02/21/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737741
Recipient Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 02/21/2025 Covered Recipient Physician A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223262700
Principal investigator 1 LivaNova USA, Inc. $17,990.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554179
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554235
Principal investigator 1 LivaNova USA, Inc. $758.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554238
Principal investigator 1 LivaNova USA, Inc. $337.50 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554243
Principal investigator 1 LivaNova USA, Inc. $270.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554247
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554252
Principal investigator 1 LivaNova USA, Inc. $1,835.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554257
Principal investigator 1 LivaNova USA, Inc. $540.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554260
Principal investigator 1 LivaNova USA, Inc. $1,885.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554265
Principal investigator 1 LivaNova USA, Inc. $83.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554268
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554375
Principal investigator 1 LivaNova USA, Inc. $1,835.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554380
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554384
Principal investigator 1 LivaNova USA, Inc. $270.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554387
Principal investigator 1 LivaNova USA, Inc. $1,835.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554391
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554395
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554399
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554404
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554408
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554413
Principal investigator 1 LivaNova USA, Inc. $758.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554417
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554421
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554424
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554428
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554432
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554436
Principal investigator 1 LivaNova USA, Inc. $1,835.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554467
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554472
Principal investigator 1 LivaNova USA, Inc. $1,835.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554475
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554479
Principal investigator 1 LivaNova USA, Inc. $590.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
OSPREY No dispute reported 06/30/2026 1245554482
Principal investigator 1 LivaNova USA, Inc. $17,990.00 02/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245554530
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614999
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615361
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615787
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616007
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617695
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618439
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618683
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620752
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621568
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621584
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623116
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626402
Principal investigator 1 Alkermes, Inc. $276.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613013
Principal investigator 1 Alkermes, Inc. $2,054.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613015
Principal investigator 1 Alkermes, Inc. $52.80 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613311
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613970
Principal investigator 1 Alkermes, Inc. $89.95 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615621
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615885
Principal investigator 1 Alkermes, Inc. $276.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616017
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616313
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616955
Principal investigator 1 Alkermes, Inc. $6.40 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617383
Principal investigator 1 Alkermes, Inc. $1,880.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617503
Principal investigator 1 Alkermes, Inc. $2,054.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617689
Principal investigator 1 Alkermes, Inc. $9.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618955
Principal investigator 1 Alkermes, Inc. $276.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619141
Principal investigator 1 Alkermes, Inc. $2,054.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619633
Principal investigator 1 Alkermes, Inc. $739.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619635
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620167
Principal investigator 1 Alkermes, Inc. $77.10 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621436
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623668
Principal investigator 1 Alkermes, Inc. $739.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625367
Principal investigator 1 Alkermes, Inc. $739.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625369
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625676
Principal investigator 1 Alkermes, Inc. $276.00 02/12/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625850
Recipient Takeda Pharmaceuticals U.S.A., Inc. $8,734.80 02/05/2025 Covered Recipient Physician TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223262698
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $412.10 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737645
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $235.30 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737647
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737649
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737651
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737657
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737661
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $913.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737663
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737665
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $159.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737667
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737669
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737671
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737673
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737675
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $215.28 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $235.30 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737679
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737681
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737683
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737685
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,644.60 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737687
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737689
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $83.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737691
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737693
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,800.50 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737695
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,177.80 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737697
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.47 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737703
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737705
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,299.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737707
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,025.10 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737709
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737711
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,654.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737713
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737719
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $314.60 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737721
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $97.50 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737723
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $527.15 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737725
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,438.50 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737727
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737731
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $128.70 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737733
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $24.70 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737735
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $31.20 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737739
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,800.50 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737743
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,800.50 02/03/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737745
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737659
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737699
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737701
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233737737
Principal investigator 1 Alkermes, Inc. $10,038.00 01/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620097
Principal investigator 1 Alkermes, Inc. $7,341.00 01/22/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626876
Principal investigator 1 Alkermes, Inc. $4,832.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613023
Principal investigator 1 Alkermes, Inc. $688.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613225
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613665
Principal investigator 1 Alkermes, Inc. $739.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613880
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614539
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614771
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615547
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616261
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616879
Principal investigator 1 Alkermes, Inc. $688.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617945
Principal investigator 1 Alkermes, Inc. $6,136.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619857
Principal investigator 1 Alkermes, Inc. $4,832.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620307
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620323
Principal investigator 1 Alkermes, Inc. $688.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621390
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621813
Principal investigator 1 Alkermes, Inc. $2,054.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621829
Principal investigator 1 Alkermes, Inc. $6,136.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623398
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623400
Principal investigator 1 Alkermes, Inc. $2,054.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623602
Principal investigator 1 Alkermes, Inc. $4,832.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624274
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624276
Principal investigator 1 Alkermes, Inc. $739.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625852
Principal investigator 1 Alkermes, Inc. $688.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625854
Principal investigator 1 Alkermes, Inc. $6,136.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625856
Principal investigator 1 Alkermes, Inc. $276.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625868
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626018
Principal investigator 1 Alkermes, Inc. $688.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626636
Principal investigator 1 Alkermes, Inc. $1,892.00 01/17/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626882
Principal investigator 1 iRhythm Technologies, Inc. $40,000.00 01/15/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
STUDY-iSLEEP No dispute reported 06/30/2026 1244039842
Principal investigator 1 Noctrix Health, Inc. $1,053.00 01/06/2025 Non-covered Recipient Entity
Bogan Sleep Consultants, LLC
THRIVE No dispute reported 06/30/2026 1254628911
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627060
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627134
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
BOGAN SLEEP CONSULTANTS, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627210